Moderna's Quarterly Earnings Preview: What You Need to Know [Yahoo! Finance]
Arbutus Biopharma Corporation (ABUS)
Last arbutus biopharma corporation earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.arbutusbio.com/node/5806
Company Research
Source: Yahoo! Finance
The Cambridge, Massachusetts-based company is expected to announce its fiscal Q1 earnings for 2026 before the market opens on Friday, May 1. Ahead of this event, analysts expect this biotechnology company to report a loss of $2.27 per share, down 9.9% from a loss of $2.52 per share in the year-ago quarter. The company has topped Wall Street's bottom-line estimates in each of the last four quarters. In Q4 2025, Moderna's loss of $2.11 per share outpaced the consensus expectations by a notable margin of 18.9%. More News from Barchart Tesla Earnings, Hormuz and Other Key Things to Watch this Week Netflix Generates Massive FCF and FCF Margins - NFLX Price Targets Are Higher Profit Jumped 58% at Taiwan Semi. Does That Make TSM Stock a Buy Here? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For the current fiscal year, ending in December, analysts expect MRNA to report a loss of $6.99 per share, 3.7% narrower than a l
Show less
Read more
Impact Snapshot
Event Time:
ABUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABUS alerts
High impacting Arbutus Biopharma Corporation news events
Weekly update
A roundup of the hottest topics
ABUS
News
- Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability [Yahoo! Finance]Yahoo! Finance
- Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis BGlobeNewswire
- Arbutus Biopharma GAAP EPS of -$0.17 misses by $0.13, revenue of $14.08M beats by $13.47M [Seeking Alpha]Seeking Alpha
- Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
ABUS
Earnings
- 8/6/25 - Beat
ABUS
Sec Filings
- 4/15/26 - Form 8-K
- 4/14/26 - Form DEFA14A
- 4/14/26 - Form DEF
- ABUS's page on the SEC website